Allogene Halts Leukemia Trial Amid Breyanzi Approval, Shifts Focus to New Therapies
Allogene Therapeutics has decided to halt its Phase I trial for cema-cel, a CD19 CAR-T cell therapy for chronic lymphocytic leukemia (CLL), as it faces increased competition from Bristol Myers Squibb's Breyanzi[1][2]. The decision was partly influenced by Breyanzi's recent approval for CLL patients, especially those treated with BTK and BCL2 inhibitors, which made Breyanzi a strong competitor in the field[2]. With patient enrollment for the trial slower than expected, Allogene is now channeling its efforts towards areas where cema-cel might offer a competitive advantage, such as large B-cell lymphoma[1][2].
References
Explore Further
What are the key factors that led Allogene to shift its focus from chronic lymphocytic leukemia to large B-cell lymphoma for cema-cel therapy?
How does the approval of Breyanzi impact the competitive landscape for CAR-T therapies targeting leukemia?
What potential advantages does Allogene see in applying CAR-T therapies to autoimmune diseases compared to traditional treatments?
In light of Allogene's strategic pivot, what are the expected challenges and opportunities in developing cema-cel for large B-cell lymphoma?
How might Allogene's exploration of CAR-T therapies for autoimmune conditions impact the broader treatment landscape for autoimmune diseases like lupus?